SMU-B is the orally active inhibitor for ALK ( IC 50 <0.5 nM), c-ros oncogene 1 (ROS1), c-MET ( IC 50 =1.87 nM) and AXL ( IC 50 =28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC 50 s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models.